查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1917791

自动化和封闭式细胞治疗市场－2026-2031年预测

Automated and Closed Cell Therapy Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 148 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计自动化和封闭式细胞疗法市场将从 2025 年的 17.68 亿美元成长到 2031 年的 42.36 亿美元，复合年增长率为 15.68%。

自动化和封闭式细胞疗法市场正透过将自动化技术融入封闭式流程而不断发展，从而提升扩充性、安全性和一致性。再生医学在医疗保健领域的日益普及也推动了市场扩张。自动化平台能够精准、大量生产，提高癌症免疫疗法（例如CAR-T疗法）的疗效。为了降低成本、减少空间占用和人工干预，人们正在大力投资紧凑型自动化系统。

自动化封闭式细胞治疗系统将封闭式生产环境与机器人和软体驱动的细胞分离、扩增、收穫、配製和填充流程结合。这些系统最大限度地降低了污染风险，实现了产品标准化，并支持个人化疗法的规模化生产。随着肿瘤学、自体免疫疾病和再生医学等领域适应症的不断拓展，对可重复、高品质细胞产品的需求日益增长，该市场正经历稳定成长。

关键成长要素包括自动化带来的多方面优势，例如：流程标准化以实现统一的处理；受控环境下更高的产量带来的可扩展扩充性；封闭环境下更低的污染；以及因减少人事费用和错误率而带来的成本效益。利用人体自身修復机制的再生医学日益普及，推动了对可靠的自动化生产的需求，以提供有效的细胞产品。随着癌症发生率的不断上升，CAR-T疗法等先进免疫疗法至关重要，而自动化封闭系统能够实现大规模、一致的、特定患者的治疗。

阻碍因素包括基础设施不足，例如许多设施无尘室使用受限以及缺乏熟练相关人员，这些都会延缓技术的普及。此外，诸如维持产品品质、在不同自动化平台间实现通讯协定标准化以及消除人们对人工监管减少的担忧等挑战，也会影响利害关係人的接受度。

从地区来看，由于技术领先、数位医疗的整合、癌症发病率上升、医护人员和患者的意识以及关键创新者的集中等因素，预计北美将占据相当大的份额。

主要企业包括 Lonza，该公司提供 Cocoon®，这是一个具有整合工作流程的自动化封闭式细胞疗法生产平台；以及 Miltenyi Biotec，该公司提供 MACS，这是一种细胞分离和富集技术，是研究和临床流程中自动化处理的基础。

总体而言，市场正在经历强劲增长，并有望透过封闭式自动化克服细胞疗法的扩充性障碍，从而在快速发展的再生医学领域中解决污染、一致性和成本方面的挑战，使更多人能够获得变革性疗法。

本报告的主要优势：

  • 深入分析：提供对主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、行业垂直领域和其他细分市场。
  • 竞争格局：了解全球主要参与者的策略倡议，并了解透过正确的策略实现市场渗透的潜力。
  • 市场驱动因素与未来趋势：探讨影响市场的动态因素和关键趋势及其对未来市场发展的影响。
  • 可操作的建议：利用这些见解，在快速变化的环境中做出策略决策，并发现新的商机和收入来源。
  • 受众广泛：对Start-Ups、研究机构、顾问公司、中小企业和大型企业都很有用且经济实惠。

公司如何使用我们的报告范例

产业与市场分析、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法规结构及影响、新产品开发、竞争情报

研究范围：

  • 2021年至2025年的历史数据和2026年至2031年的预测数据
  • 成长机会、挑战、供应链前景、法规结构与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 按业务板块和地区（包括国家）分類的收入和预测评估
  • 公司概况（策略、产品、财务资讯、关键发展等）

目录

第一章执行摘要

第二章 市场概览

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策与法规
  • 策略建议

第四章 技术展望

第五章 自动化/封闭式细胞疗法市场：依治疗方法划分

  • 介绍
  • 干细胞疗法
  • 非干细胞疗法

第六章 自动化/封闭式细胞疗法市场：依规模划分

  • 介绍
  • 商业化前/研发规模
  • 商业规模

第七章 按最终使用者分類的自动化和封闭式细胞治疗市场

  • 介绍
  • 製药和生物技术公司
  • 研究和学术机构
  • 其他的

第八章：按地区分類的自动化和封闭式细胞治疗市场

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 合併、收购、协议和合作
  • 竞争对手仪錶板

第十章：公司简介

  • Miltenyi Biotec
  • Lonza
  • Fresenius Kabi
  • Danaher Corporation
  • BioSpherix, LLC
  • Terumo Corporation
  • Sartorius AG
  • ThermoGenesis
  • Cellares Inc.
  • Thermo Fisher Scientific, Inc.
  • Merck KgaA

第十一章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061615765

Automated And Closed Cell Therapy Market is expected to grow at a 15.68% CAGR, increasing to USD 4.236 billion in 2031 from USD 1.768 billion in 2025.

The automated and closed cell therapy market is advancing through integration of automation in closed-system processes, enhancing scalability, safety, and consistency. Rising adoption of regenerative medicine across healthcare sectors is accelerating market expansion. Automated platforms are improving treatment efficacy in cancer immunotherapies such as CAR-T by enabling precise, high-volume production. Significant investments are flowing into compact, automated systems to lower costs, space requirements, and manual intervention.

Automated and closed cell therapy combines closed manufacturing environments with robotic or software-driven processes for cell isolation, expansion, harvesting, formulation, and fill-finish. These systems minimize contamination risks, standardize outputs, and support scalable production of personalized therapies. The market is growing steadily, driven by demand for reproducible, high-quality cellular products amid expanding indications in oncology, autoimmune diseases, and regenerative applications.

Key growth drivers include the multifaceted benefits of automation, such as process standardization for uniform therapies, enhanced scalability through higher yields in controlled settings, reduced contamination in closed environments, and cost efficiencies via lowered labor and error rates. Increasing popularity of regenerative medicine, focused on harnessing innate repair mechanisms, amplifies needs for reliable, automated manufacturing to deliver viable cell products. Growing cancer prevalence necessitates advanced immunotherapies like CAR-T, where automated closed systems ensure consistent, patient-specific engineering at scale.

Restraints encompass infrastructure gaps, including limited cleanroom access and skilled personnel at many facilities, potentially slowing adoption. Challenges in maintaining product quality, standardizing protocols across automated platforms, and addressing perceptions of reduced human oversight may influence stakeholder acceptance.

Geographically, North America is expected to hold significant share, supported by technological leadership, digital healthcare integration, elevated cancer incidence, provider/patient awareness, and concentration of key innovators.

Leading companies include Lonza, offering the Cocoon(R) platform for automated, closed cell therapy manufacturing with integrated workflows. Miltenyi Biotec provides MACS technology for cell isolation and enrichment, foundational to automated processing in research and clinical pipelines.

Overall, the market is progressing robustly, positioned to overcome scalability barriers in cell therapy through closed automation, enabling broader access to transformative treatments while addressing contamination, consistency, and cost challenges in a rapidly evolving regenerative landscape.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Automated and Closed Cell Therapy Market Segmentation

  • By Therapy Type
  • Stem-Cell Therapy
  • Non-Stem-Cell Therapy
  • By Scale
  • Pre-Commercial / R&D Scale
  • Commercial Scale
  • By End-User
  • Pharmaceuticals & Bio-Tech Companies
  • Research & Academic Institute
  • Others
  • By Geography
  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. AUTOMATED AND CLOSED SELL THERAPY MARKET BY THERAPY TYPE

  • 5.1. Introduction
  • 5.2. Stem-Cell Therapy
  • 5.3. Non-Stem-Cell Therapy

6. AUTOMATED AND CLOSED SELL THERAPY MARKET BY SCALE

  • 6.1. Introduction
  • 6.2. Pre-Commercial / R&D Scale
  • 6.3. Commercial Scale

7. AUTOMATED AND CLOSED SELL THERAPY MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Pharmaceuticals & Bio-Tech Companies
  • 7.3. Research & Academic Institute
  • 7.4. Others

8. AUTOMATED AND CLOSED SELL THERAPY MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Miltenyi Biotec
  • 10.2. Lonza
  • 10.3. Fresenius Kabi
  • 10.4. Danaher Corporation
  • 10.5. BioSpherix, LLC
  • 10.6. Terumo Corporation
  • 10.7. Sartorius AG
  • 10.8. ThermoGenesis
  • 10.9. Cellares Inc.
  • 10.10. Thermo Fisher Scientific, Inc.
  • 10.11. Merck KgaA

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations